Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Teva Pharmaceutical Industries Ltd
Teva to Present at the Upcoming Investor Conferences in March
April 29, 2026
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
April 29, 2026
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
January 27, 2026
←
Previous Page
1
2
3